Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation (Tables)

Share-based compensation (Tables)

6 Months Ended

Jun. 30, 2019

Summary of share-based compensation expense included in the unaudited consolidated statements of operations

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended			Six months ended
		June 30,			June 30,
	2019		2018		2019		2018
Research and development	$	786	$	2,071	$	2,807	$	4,285
General and administrative		2,410		2,008		3,868		4,126
	$	3,196	$	4,079	$	6,675	$	8,411

Summary of share options and options which have a nominal exercise price

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended			Six months ended
		June 30,			June 30,
	2019		2018		2019		2018
Number of options over ordinary shares granted		936,696		1,435,685		11,743,896		11,430,341
Weighted average fair value of ordinary shares options	$	0.39	$	1.18	$	0.54	$	0.80
Number of additional options with a nominal exercise price granted		459,240		151,056		6,957,366		6,703,692
Weighted average fair value of options with a nominal exercise price	$	0.70		1.88	$	0.93	$	1.35